{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:12:50Z","timestamp":1789726370377,"version":"4.0.1"},"reference-count":65,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T00:00:00Z","timestamp":1724716800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","jiac-j.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.jiac.2024.08.016","type":"journal-article","created":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T09:04:02Z","timestamp":1724749442000},"page":"102501","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Association between age and onset of daptomycin-induced adverse events using the U.S. food and drug administration adverse event reporting system"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1190-6540","authenticated-orcid":false,"given":"Chihiro","family":"Shiraishi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5272-9560","authenticated-orcid":false,"given":"Hideo","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Ogura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Iwamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jiac.2024.08.016_bib1","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.ijantimicag.2012.12.008","article-title":"Safety of daptomycin in patients completing more than 14 days of therapy: results from the cubicin\u00ae outcomes registry and experience","volume":"41","author":"Rege","year":"2013","journal-title":"Int J Antimicrob Agents"},{"issue":"2","key":"10.1016\/j.jiac.2024.08.016_bib2","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ijantimicag.2010.03.015","article-title":"Efficacy and safety of daptomycin in the treatment of Gram-positive catheter-related bloodstream infections in cancer patients","volume":"36","author":"Chaftari","year":"2010","journal-title":"Int J Antimicrob Agents"},{"issue":"5","key":"10.1016\/j.jiac.2024.08.016_bib3","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.ijantimicag.2013.01.019","article-title":"Daptomycin for outpatient parenteral antibiotic therapy: a European registry experience","volume":"41","author":"Seaton","year":"2013","journal-title":"Int J Antimicrob Agents"},{"issue":"4","key":"10.1016\/j.jiac.2024.08.016_bib4","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1128\/CMR.00030-13","article-title":"A current perspective on daptomycin for the clinical microbiologist","volume":"26","author":"Humphries","year":"2013","journal-title":"Clin Microbiol Rev"},{"issue":"12","key":"10.1016\/j.jiac.2024.08.016_bib5","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1038\/nrd1258","article-title":"Daptomycin","volume":"2","author":"Kirkpatrick","year":"2003","journal-title":"Nat Rev Drug Discov"},{"issue":"7","key":"10.1016\/j.jiac.2024.08.016_bib6","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa053783","article-title":"Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus","volume":"355","author":"Fowler","year":"2006","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jiac.2024.08.016_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jac\/dkx349","article-title":"Daptomycin","volume":"73","author":"Heidary","year":"2018","journal-title":"J Antimicrob Chemother"},{"issue":"24","key":"10.1016\/j.jiac.2024.08.016_bib8","doi-asserted-by":"crossref","first-page":"6253","DOI":"10.1016\/j.bmc.2016.05.052","article-title":"The action mechanism of daptomycin","volume":"24","author":"Taylor","year":"2016","journal-title":"Bioorg Med Chem"},{"issue":"suppl 2","key":"10.1016\/j.jiac.2024.08.016_bib9","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.1086\/499406","article-title":"The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs","volume":"42","author":"Cosgrove","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"suppl 1","key":"10.1016\/j.jiac.2024.08.016_bib10","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/j.earlhumdev.2011.01.007","article-title":"Drug policy in Europe research and funding in neonates: current challenges, future perspectives, new opportunities","volume":"87","author":"Jacqz-Aigrain","year":"2011","journal-title":"Early Hum Dev"},{"issue":"3","key":"10.1016\/j.jiac.2024.08.016_bib11","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.phrs.2011.01.016","article-title":"The development of medicines for children. Part of a series on pediatric pharmacology","volume":"64","author":"Rocchi","year":"2011","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.jiac.2024.08.016_bib12","series-title":"Merck sharp & dohme","article-title":"Prescribing information","year":"2020"},{"key":"10.1016\/j.jiac.2024.08.016_bib13","series-title":"Cubicin 350 and 500 mg, Summary of Product Characteristics","year":"2010"},{"issue":"2","key":"10.1016\/j.jiac.2024.08.016_bib14","first-page":"127","article-title":"Daptomycin use for children","volume":"27","author":"Okui","year":"2015","journal-title":"Japanese Society for Pediatric Infectious Diseases"},{"issue":"4","key":"10.1016\/j.jiac.2024.08.016_bib15","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.2196\/medinform.6437","article-title":"Population analysis of adverse events in different age groups using big clinical trials data","volume":"4","author":"Luo","year":"2016","journal-title":"JMIR Med Inform"},{"key":"10.1016\/j.jiac.2024.08.016_bib16","unstructured":"Daptomycin U.S. FOOD&DRUG administration. Last updated: 25 January 2022. 213645s000lbl.pdf (fda.gov)."},{"key":"10.1016\/j.jiac.2024.08.016_bib17","unstructured":"Cubicin. Last updated: 20 June 2024. Cubicin | European Medicines Agency ([europa.eu])."},{"issue":"1","key":"10.1016\/j.jiac.2024.08.016_bib18","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s12888-020-02525-z","article-title":"Adverse event reports in patients taking psychiatric medication during pregnancy from spontaneous reports in Japan and the United States: an approach using latent class analysis","volume":"20","author":"Anzai","year":"2020","journal-title":"BMC Psychiatr"},{"issue":"7","key":"10.1016\/j.jiac.2024.08.016_bib19","doi-asserted-by":"crossref","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA adverse event reporting system","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int J Med Sci"},{"issue":"35","key":"10.1016\/j.jiac.2024.08.016_bib20","first-page":"9908","article-title":"E2B(R3) electronic transmission of individual case safety reports; data elements and message specification; appendix on backwards and forwards compatibility; availability. Notice","volume":"79","year":"2014","journal-title":"Fed Regist"},{"key":"10.1016\/j.jiac.2024.08.016_bib21","first-page":"266","article-title":"Data mining techniques in pharmacovigilance: analysis of the publicly accessible FDA adverse event reporting system (AERS)","volume":"12","author":"Poluzzi","year":"2012","journal-title":"Intech"},{"issue":"3","key":"10.1016\/j.jiac.2024.08.016_bib22","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1002\/cam4.5062","article-title":"Hematological toxicities in PARP inhibitors: a real-world study using FDA Adverse Event Reporting System (FAERS) database","volume":"12","author":"Shu","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.jiac.2024.08.016_bib23","series-title":"Guidance for industry: general considerations for pediatric pharmacokinetic studies for drugs and biological products","year":"1998"},{"issue":"5","key":"10.1016\/j.jiac.2024.08.016_bib28","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1007\/s43441-021-00309-5","article-title":"Factors influencing classifications of safety specifications in a risk management plan for antineoplastic agents approved in Japan: a review and descriptive analysis","volume":"55","author":"Ezaki","year":"2021","journal-title":"Ther Innov Regul Sci."},{"issue":"25","key":"10.1016\/j.jiac.2024.08.016_bib29","first-page":"e1082","article-title":"AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American college of cardiology\/American heart association task force on clinical practice guidelines","volume":"139","author":"Grundy","year":"2018","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.jiac.2024.08.016_bib30","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1111\/bcp.13216","article-title":"The drugs that mostly frequently induce acute kidney injury: a case - noncase study of a pharmacovigilance database","volume":"83","author":"Pierson-Marchandise","year":"2017","journal-title":"Br J Clin Pharmacol"},{"issue":"11","key":"10.1016\/j.jiac.2024.08.016_bib31","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1016\/j.ekir.2023.08.031","article-title":"Overview of antibiotic-induced nephrotoxicity","volume":"8","author":"Campbell","year":"2023","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.jiac.2024.08.016_bib32","series-title":"R: a language and environment for statistical computing","year":"2022"},{"issue":"1","key":"10.1016\/j.jiac.2024.08.016_bib33","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1002\/cam4.1920","article-title":"Pharmacovigilance evaluation of the relationship between impaired glucose metabolism and BCR-ABL inhibitor use by using an adverse drug event reporting database","volume":"8","author":"Okada","year":"2019","journal-title":"Cancer Med"},{"issue":"5","key":"10.1016\/j.jiac.2024.08.016_bib34","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/ACI.0000000000000568","article-title":"Gender differences in anaphylaxis","volume":"19","author":"Salvati","year":"2019","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"7","key":"10.1016\/j.jiac.2024.08.016_bib35","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1097\/MEG.0000000000000614","article-title":"Predictors of fecal transplant failure","volume":"28","author":"Meighani","year":"2016","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jiac.2024.08.016_bib36","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1002\/cam4.5062","article-title":"Hematological toxicities in PARP inhibitors: a real-world study using FDA Adverse Event Reporting System (FAERS) database","volume":"12","author":"Shu","year":"2023","journal-title":"Cancer Med"},{"issue":"12","key":"10.1016\/j.jiac.2024.08.016_bib37","doi-asserted-by":"crossref","first-page":"3181","DOI":"10.1093\/jac\/dku277","article-title":"Efficacy and safety of daptomycin for the treatment of infectious disease: a meta-analysis based on randomized controlled trials","volume":"69","author":"He","year":"2014","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"10.1016\/j.jiac.2024.08.016_bib38","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1128\/AAC.00247-06","article-title":"Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers","volume":"50","author":"Benvenuto","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"10.1016\/j.jiac.2024.08.016_bib39","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1086\/430352","article-title":"Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact","volume":"191","author":"Silverman","year":"2005","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.jiac.2024.08.016_bib40","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0272-5231(03)00141-2","article-title":"Drug-induced eosinophilic lung disease","volume":"25","author":"Allen","year":"2004","journal-title":"Clin Chest Med"},{"key":"10.1016\/j.jiac.2024.08.016_bib41","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13756-016-0158-8","article-title":"Daptomycin-induced eosinophilic pneumonia - a systematic review","volume":"5","author":"Uppal","year":"2016","journal-title":"Antimicrob Resist Infect Control"},{"issue":"4","key":"10.1016\/j.jiac.2024.08.016_bib42","doi-asserted-by":"crossref","first-page":"e211","DOI":"10.1016\/j.jinf.2006.11.006","article-title":"Eosinophilic pneumonia induced by daptomycin","volume":"54","author":"Hayes","year":"2007","journal-title":"J Infect"},{"issue":"9","key":"10.1016\/j.jiac.2024.08.016_bib43","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1164\/rccm.2112056","article-title":"Idiopathic acute eosinophilic pneumonia","volume":"166","author":"Philit","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.jiac.2024.08.016_bib44","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2169\/internalmedicine.9010-17","article-title":"Daptomycin-induced eosinophilic pneumonia and a review of the published literature","volume":"57","author":"Higashi","year":"2018","journal-title":"Intern Med"},{"issue":"2","key":"10.1016\/j.jiac.2024.08.016_bib45","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1055\/s-2006-939522","article-title":"Drug-, toxin-, and radiation therapy-induced eosinophilic pneumonia","volume":"27","author":"Solomon","year":"2006","journal-title":"Semin Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.jiac.2024.08.016_bib46","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1128\/AAC.47.4.1318-1323.2003","article-title":"Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects","volume":"47","author":"Dvorchik","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"10.1016\/j.jiac.2024.08.016_bib47","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac577","article-title":"Seventeen cases of daptomycin-induced eosinophilic pneumonia in a cohort of patients treated for bone and joint infections: proposal for a new algorithm","volume":"9","author":"Pham","year":"2022","journal-title":"Open Forum Infect Dis"},{"issue":"4","key":"10.1016\/j.jiac.2024.08.016_bib48","doi-asserted-by":"crossref","first-page":"446","DOI":"10.3390\/antibiotics10040446","article-title":"Risk factors of daptomycin-induced eosinophilic pneumonia in a population with osteoarticular infection","volume":"10","author":"Soldevila-Boixader","year":"2021","journal-title":"Antibiotics"},{"issue":"5","key":"10.1016\/j.jiac.2024.08.016_bib49","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1086\/650487","article-title":"Two cases of daptomycin-induced eosinophilic pneumonia and chronic pneumonitis","volume":"50","author":"Lal","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.1016\/j.jiac.2024.08.016_bib50","doi-asserted-by":"crossref","first-page":"e63","DOI":"10.1086\/652656","article-title":"Acute eosinophilic pneumonia secondary to daptomycin: a report of three cases","volume":"50","author":"Miller","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.jiac.2024.08.016_bib51","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.rmedc.2008.07.010","article-title":"Acute respiratory failure due to daptomycin induced eosinophilic pneumonia","volume":"1","author":"Kakish","year":"2008","journal-title":"Respir Med CME"},{"issue":"1","key":"10.1016\/j.jiac.2024.08.016_bib52","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-56534-4","article-title":"Comorbidity status in hospitalized elderly in Japan: analysis from national database of health insurance claims and specific health checkups","volume":"9","author":"Nojiri","year":"2019","journal-title":"Sci Rep"},{"issue":"7\u20138","key":"10.1016\/j.jiac.2024.08.016_bib53","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1111\/jocn.15595","article-title":"Polypharmacy and pattern of medication use in community-dwelling older adults: a systematic review","volume":"30","author":"Hsu","year":"2021","journal-title":"J Clin Nurs"},{"issue":"1","key":"10.1016\/j.jiac.2024.08.016_bib54","doi-asserted-by":"crossref","first-page":"5754","DOI":"10.1038\/s41598-023-32663-9","article-title":"Association between cumulative smoking exposure and cognitive decline in non-demented older adults: NEDICES study","volume":"13","author":"Benito-Le\u00f3n","year":"2023","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.jiac.2024.08.016_bib55","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1345\/aph.1K579","article-title":"Daptomycin-induced acute renal and hepatic toxicity without rhabdomyolysis","volume":"42","author":"Abraham","year":"2008","journal-title":"Ann Pharmacother"},{"issue":"6","key":"10.1016\/j.jiac.2024.08.016_bib56","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1111\/bcp.13216","article-title":"The drugs that mostly frequently induce acute kidney injury: a case - noncase study of a pharmacovigilance database","volume":"83","author":"Pierson-Marchandise","year":"2017","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.jiac.2024.08.016_bib57","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1053\/j.gastro.2014.01.059","article-title":"Role of the intestinal microbiota in resistance to colonization by Clostridium difficile","volume":"146","author":"Britton","year":"2014","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.jiac.2024.08.016_bib58","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/jac\/dkr508","article-title":"Time interval of increased risk for Clostridium difficile infection after exposure to antibiotics","volume":"67","author":"Hensgens","year":"2012","journal-title":"J Antimicrob Chemother"},{"issue":"9","key":"10.1016\/j.jiac.2024.08.016_bib59","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1056\/NEJMoa1408913","article-title":"Burden of Clostridium difficile infection in the United States","volume":"372","author":"Lessa","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jiac.2024.08.016_bib60","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s40121-016-0111-4","article-title":"Acute angioedema triggered by daptomycin","volume":"5","author":"Gisler","year":"2016","journal-title":"Infect Dis Ther"},{"issue":"Suppl 3","key":"10.1016\/j.jiac.2024.08.016_bib61","first-page":"30","article-title":"Drug-induced anaphylaxis in children","volume":"90","author":"Cardinale","year":"2019","journal-title":"Acta Biomed"},{"key":"10.1016\/j.jiac.2024.08.016_bib62","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/00005792-198205000-00002","article-title":"The spectrum of rhabdomyolysis","volume":"62","author":"Gabow","year":"1982","journal-title":"Medicine"},{"issue":"6","key":"10.1016\/j.jiac.2024.08.016_bib63","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1093\/ndt\/9.6.637","article-title":"Relationship between elevated creatine phosphokinase and the clinical spectrum of rhabdomyolysis","volume":"9","author":"Veenstra","year":"1994","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jiac.2024.08.016_bib64","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2016-2477","article-title":"Daptomycin for complicated skin infections: a randomized trial","volume":"139","author":"Bradley","year":"2017","journal-title":"Pediatrics"},{"key":"10.1016\/j.jiac.2024.08.016_bib65","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1097\/INF.0000000000001926","article-title":"Randomized multicenter study comparing safety and efficacy of daptomycin versus standard-of-care in pediatric patients with staphylococcal bacteremia","volume":"37","author":"Arrieta","year":"2018","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.jiac.2024.08.016_bib66","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.jiac.2021.11.019","article-title":"Efficacy and safety of daptomycin in Japanese pediatric participants with complicated skin and soft tissue infections or bacteremia caused by gram-positive cocci","volume":"28","author":"Iwata","year":"2022","journal-title":"J Infect Chemother"},{"issue":"11","key":"10.1016\/j.jiac.2024.08.016_bib67","doi-asserted-by":"crossref","first-page":"5626","DOI":"10.1128\/AAC.00038-12","article-title":"Randomized controlled trial of the safety and efficacy of daptomycin versus standard-of-care therapy for management of patients with osteomyelitis associated with prosthetic devices undergoing two-stage revision arthroplasty","volume":"56","author":"Byren","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2024.08.016_bib68","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa053783","article-title":"Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus","volume":"355","author":"Fowler","year":"2006","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.jiac.2024.08.016_bib69","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/nbt.3623","article-title":"Data mining differential clinical outcomes associated with drug regimens using adverse event reporting data","volume":"34","author":"Sarangdhar","year":"2016","journal-title":"Nat Biotechnol"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X24002332?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X24002332?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T11:43:27Z","timestamp":1736768607000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X24002332"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":65,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S1341321X24002332"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2024.08.016","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association between age and onset of daptomycin-induced adverse events using the U.S. food and drug administration adverse event reporting system","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2024.08.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102501"}}